These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32895473)

  • 1. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
    Guan Y; Greenberg EF; Hasipek M; Chen S; Liu X; Kerr CM; Gackowski D; Zarakowska E; Radivoyevitch T; Gu X; Willard B; Visconte V; Makishima H; Nazha A; Mukherji M; Sekeres MA; Saunthararajah Y; Oliński R; Xu M; Maciejewski JP; Jha BK
    Commun Biol; 2020 Sep; 3(1):493. PubMed ID: 32895473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia.
    Mancini M; Veljkovic N; Leo E; Aluigi M; Borsi E; Galloni C; Iacobucci I; Barbieri E; Santucci MA
    J Cell Biochem; 2012 Aug; 113(8):2765-74. PubMed ID: 22467095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
    Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
    Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
    [No Abstract]   [Full Text] [Related]  

  • 4. TET2 mutation as prototypic clonal hematopoiesis lesion.
    Guarnera L; Jha BK
    Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invariant phenotype and molecular association of biallelic
    Awada H; Nagata Y; Goyal A; Asad MF; Patel B; Hirsch CM; Kuzmanovic T; Guan Y; Przychodzen BP; Aly M; Adema V; Shen W; Williams L; Nazha A; Abazeed ME; Sekeres MA; Radivoyevitch T; Haferlach T; Jha BK; Visconte V; Maciejewski JP
    Blood Adv; 2019 Feb; 3(3):339-349. PubMed ID: 30709865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities.
    Montagner S; Leoni C; Emming S; Della Chiara G; Balestrieri C; Barozzi I; Piccolo V; Togher S; Ko M; Rao A; Natoli G; Monticelli S
    Cell Rep; 2016 May; 15(7):1566-1579. PubMed ID: 27160912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals.
    Yin R; Mao SQ; Zhao B; Chong Z; Yang Y; Zhao C; Zhang D; Huang H; Gao J; Li Z; Jiao Y; Li C; Liu S; Wu D; Gu W; Yang YG; Xu GL; Wang H
    J Am Chem Soc; 2013 Jul; 135(28):10396-403. PubMed ID: 23768208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.
    Guan Y; Hasipek M; Tiwari AD; Maciejewski JP; Jha BK
    Semin Hematol; 2021 Jan; 58(1):27-34. PubMed ID: 33509440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine.
    Minor EA; Court BL; Young JI; Wang G
    J Biol Chem; 2013 May; 288(19):13669-74. PubMed ID: 23548903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.
    Makishima H; Jankowska AM; McDevitt MA; O'Keefe C; Dujardin S; Cazzolli H; Przychodzen B; Prince C; Nicoll J; Siddaiah H; Shaik M; Szpurka H; Hsi E; Advani A; Paquette R; Maciejewski JP
    Blood; 2011 May; 117(21):e198-206. PubMed ID: 21346257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis.
    Zhang S; Yu H; Li J; Fan J; Chen J
    Bioengineered; 2022 Feb; 13(2):3470-3485. PubMed ID: 35068331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.
    Zhang Q; Zhao K; Shen Q; Han Y; Gu Y; Li X; Zhao D; Liu Y; Wang C; Zhang X; Su X; Liu J; Ge W; Levine RL; Li N; Cao X
    Nature; 2015 Sep; 525(7569):389-393. PubMed ID: 26287468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.
    Deplus R; Delatte B; Schwinn MK; Defrance M; Méndez J; Murphy N; Dawson MA; Volkmar M; Putmans P; Calonne E; Shih AH; Levine RL; Bernard O; Mercher T; Solary E; Urh M; Daniels DL; Fuks F
    EMBO J; 2013 Mar; 32(5):645-55. PubMed ID: 23353889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX.
    Ko M; An J; Bandukwala HS; Chavez L; Aijö T; Pastor WA; Segal MF; Li H; Koh KP; Lähdesmäki H; Hogan PG; Aravind L; Rao A
    Nature; 2013 May; 497(7447):122-6. PubMed ID: 23563267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
    Roche-Lestienne C; Marceau A; Labis E; Nibourel O; Coiteux V; Guilhot J; Legros L; Nicolini F; Rousselot P; Gardembas M; Helevaut N; Frimat C; Mahon FX; Guilhot F; Preudhomme C;
    Leukemia; 2011 Oct; 25(10):1661-4. PubMed ID: 21637286
    [No Abstract]   [Full Text] [Related]  

  • 19. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages.
    Cobo I; Tanaka TN; Chandra Mangalhara K; Lana A; Yeang C; Han C; Schlachetzki J; Challcombe J; Fixsen BR; Sakai M; Li RZ; Fields H; Mokry M; Tsai RG; Bejar R; Prange K; de Winther M; Shadel GS; Glass CK
    Immunity; 2022 Aug; 55(8):1386-1401.e10. PubMed ID: 35931086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
    Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
    Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.